The Leaked Hidden Secret For Pritelivir Discovered

Human leucocyte antigen was also demonstrated to play an important role in MTCT. A large multivariate analysis showed that mother and child concordance http://www.selleckchem.com/products/gsk2126458.html at any HLA class I but not class II locus is a strong predictor of MTCT [140, 141]; however, no specific maternal HLA locus was associated with transmission. By contrast, other studies showed a predictive value of specific HLA genes. In one study, approximately half of the mothers who transmitted with low viral loads had HLA-B*1302, B*3501, B*3503, B*4402 or B*5001 alleles [57] whereas, in another study, decreased MTCT risk was strongly associated with a functional cluster of related HLA alleles, the A2/6802 supertype [142]. It is clear from the above discussion that it is currently not possible to assess the absolute risk of MTCT of HIV-1 in the individual pregnant woman. The predictive values of a combination of factors may be more relevant than each factor considered alone. In 1994, the first clinical trial http://www.selleckchem.com/products/bay-57-1293.html of MTCT (ACTG076), a collaboration between groups in the USA and France, provided proof of the concept that antiretroviral therapy could substantially decrease the risk of transmission (Fig.?4) [143]. ZDV administered to the pregnant women from the second trimester of gestation and to the baby for 1?month reduced transmission by approximately two-thirds compared with the placebo-treated group. Since then, clinical trials performed in resource-limited countries have demonstrated that ZDV prophylaxis with shorter protocols, which are more appropriate for the local conditions, is safe and can reduce the number of transmission events by approximately half [144�C146]. A Thai study (PHPT-1) provided evidence that a longer (from 28?weeks of http://www.selleck.cn/products/CAL-101.html gestation) antepartum treatment duration was significantly more effective than a shorter period of therapy (from 35?weeks of gestation) (1.6% vs. 5.1% transmission, respectively), showing also that a significant proportion of in utero infections occurs during the last trimester of gestation [145]. This study also demonstrated that longer treatment in the infant could not substitute for a longer period of treatment in the mother. During the same time, national guidelines in several European countries and the USA were modified. Elective Caesarean section was widely introduced, women were more frequently treated with a combination of antiretroviral drugs and infants were treated for only 1?week postpartum. Together, these changes reduced the transmission rates to